Oluwadunni E. Emiloju, MBBS, MS
-
RoleMedical Oncology
-
Practicing Since2024
Background
A medical oncologist, Oluwadunni Emiloju, MBBS, MS, specializes in the treatment of gastrointestinal cancers. She joined the clinical staff at Winship Cancer Institute as an attending physician in 2024. Dr. Emiloju is an assistant professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine.
Titles & Roles
-
Assistant Professor, Department of Hematology and Medical OncologyEmory University School of Medicine
Education & Training
Education
- Fellowship, Oncology/Hematology, 2024Mayo Clinic College of Medicine and Science
- Residency, Internal Medicine, 2021Einstein Medical Center
- Internship, Internal Medicine, 2020Einstein Medical Center
- Internship, 2010University College Hospital, Ibadan, Nigeria
- Medical Education, MD, 2009University of Ibadan College of Medicine
Board Certifications
- Medical OncologyAmerican Board of Internal Medicine, 2024HematologyAmerican Board of Internal Medicine, 2024Internal MedicineAmerican Board of Internal Medicine, 2020
Professional Memberships
- American Society of Clinical Oncology
- American Society of Hematology
- European Society for Medical Oncology
Research
Dr. Emiloju's research interests include:
- Mechanisms and biomarkers of primary resistance to immune checkpoint inhibition in mismatch repair deficient metastatic colorectal cancer.
- Premalignant lesions in early-onset colorectal cancer, and opportunities for interception.
- Biomarker development for early detection of colorectal cancer using RNA sequencing.
- Outcomes of early-onset colorectal cancer with synchronous oligometastases: improving patient selection for oligometastasectomy.
- Improving response to immunotherapy in mismatch reapir proficient metastatic cancer through the use of cancer vaccines in combination with chemotherapy.
- Exploiting combinatorial approaches targetting DNA damage repair pathways in advanced pancreatic adenocarcinoma and biliary tract cancers.
- Preemptive pharmacogenomic testing for dihydropyridine dehydrogenase deficiency, correlation of abnormal DPYD genotype with clinical phenotype.
Ratings & Reviews
Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.